Teyi Pharmaceutical Group Co Ltd

Teyi Pharmaceutical Group Co Ltd has a market capitalization of 4.49 billion CNY and a price-to-earnings ratio of 54.99, which is significantly higher than the industry median, indicating a premium valuation relative to earnings. The company's price-to-book ratio of 2.47 suggests that the market values the company at more than double its book value. The enterprise value to EBITDA ratio of 59.29 is also elevated, reflecting a high multiple on operating performance.

The company's profitability metrics show a return on equity of 4.48% and a return on assets of 3.53%, both of which are below the industry median for pharmaceutical firms. This suggests that Teyi is underperforming in terms of capital efficiency and asset utilization compared to its peers. The gross profit margin of 54.5% is in line with the industry, but the operating margin of 8.7% is below the median, indicating higher operating costs or lower pricing power.

Teyi's revenue is concentrated in a single geographic market, with all reported revenue derived from domestic operations. The company does not disclose segment-level revenue, but its product portfolio is likely diversified across therapeutic areas. The lack of international exposure reduces diversification but also limits growth potential outside China.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest period. Analysts expect a slight improvement in earnings, with a mean EPS estimate of 0.45 CNY for the current fiscal year, compared to the actual EPS of 0.16 CNY in the previous period. This suggests a projected increase of 181%, but the current P/E ratio implies that the market is not pricing in this growth.

Teyi faces moderate liquidity risk, with a current ratio of 1.89 and a debt-to-equity ratio of 0.15. The company has 271.6 million CNY in long-term debt and 46.5 million CNY in free cash flow, which is insufficient to cover the debt in the short term. The risk assessment also flags a negative net cash position after subtracting total debt, which could constrain the company's ability to invest in growth opportunities.

Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's capital expenditure of -79.5 million CNY suggests a reduction in investment, which may reflect a focus on cost control rather than expansion. There are no recent dilution events, and the number of shares outstanding has remained unchanged, indicating a stable capital structure.

Teyi Pharmaceutical Group Co Ltd (002728.SZ) has undergone a formal classification update, with its economic sector now explicitly identified as Healthcare and its primary activity defined as Pharmaceuticals. This structural clarification serves as the most material change in the company's profile, establishing a clear baseline for sector-specific analysis and aligning the firm’s operational identity with its core business functions. In terms of risk assessment, the company’s dilution risk has been categorized as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This assessment provides a foundational layer of security for investors, suggesting that existing equity holders are not currently facing significant pressure from aggressive capital raising or dilutive financing activities. Conversely, the liquidity risk has been assessed at a medium level. This designation highlights a moderate degree of uncertainty regarding the company’s ability to meet short-term obligations or the ease with which its shares can be traded without significant price impact. While not critical, this medium rating warrants attention for investors monitoring cash flow stability and market depth. The COMPANY_360 data indicates that the firm currently has no recorded analyst coverage, index memberships, or disclosed top holders in the provided dataset. This lack of external tracking metrics suggests that the recent changes represent an internal data normalization or initial profiling event rather than a reaction to external market movements or institutional shifts. The synthesis of these factors points to a company with a clearly defined pharmaceutical focus and low dilution risk, but with moderate liquidity considerations and limited current external analyst visibility.